Eli Lilly reported first-quarter 2026 financial results this morning, and the print is the kind of quarter that resets analyst expectations across the obesity drug category. Total revenue of $19.8 billion, up 56% year-over-year. Combined Mounjaro and Zepbound revenue of $12.8 billion in the quarter alone—a number larger than the total annual revenue of most pharmaceutical companies. EPS of $8.26 on a reported basis, up 170%. Lilly raised full-year 2026 revenue guidance to $82–85 billion, from the previous range of $80–83 billion. (Lilly investor release; CNBC)

The headline numbers are what they are. The strategic information embedded in the call is what matters going forward.

The Incretin Franchise Is Still Accelerating

Lilly’s tirzepatide franchise—Mounjaro for type 2 diabetes and Zepbound for obesity—generated $12.8 billion in Q1 revenue. Mounjaro alone hit $8.7 billion, up 125% year-over-year, with more than half of that revenue now coming from international markets. Zepbound came in at $4.16 billion in U.S. sales, an 80% increase versus the prior-year quarter.

The growth profile matters because it suggests the GLP-1 obesity market is still expanding rather than maturing. Year three of widespread availability is normally when revenue acceleration slows—pricing pressure, generic competition, and saturation of the eligible patient population start to compress growth. Tirzepatide is showing none of that. The international expansion is contributing, the diabetes-versus-obesity revenue mix is broadening, and the patient population willing to pay for a meaningfully more effective weight-loss drug than semaglutide appears to still be increasing.

Lilly’s framing on the call was that volume growth is doing the work, partially offset by lower realized prices. That dynamic—volume up, price down—is the pattern that suggests demand is still well ahead of access, and that price negotiation pressure is being absorbed into market expansion rather than into margin compression.

Foundayo Is in the Field

Lilly received FDA approval for Foundayo (orforglipron) on April 1, 2026, under the FDA’s Commissioner’s National Priority Voucher pilot—the first new molecular entity approved under that pathway, and the fastest NME approval since 2002. The drug is a once-daily oral GLP-1 receptor agonist for adult obesity and overweight with weight-related comorbidity, with no food or water restriction on dosing.

The early commercial trajectory is being closely watched. IQVIA Week 2 data showed 3,707 prescriptions; Week 3 showed 5,612. The numbers are growing, but trail Novo Nordisk’s Wegovy pill—running at approximately 50,000 weekly U.S. prescriptions in early 2026—by a 5:1 ratio. The CNPV-pilot approval pathway was extraordinarily fast (50 days from filing), which may have left commercial infrastructure—payer formulary placement, pharmacy stocking, prescriber familiarity—less ready than it would have been on a normal timeline. The next several weeks of IQVIA data will inform whether Foundayo’s uptake curve accelerates into the typical launch trajectory or stays in the slower-build pattern. The full Foundayo deep dive is forthcoming.

TRIUMPH-1 Is Imminent

The single most consequential pipeline detail from the earnings call: Lilly confirmed that TRIUMPH-1—the Phase 3 trial of retatrutide in adults with obesity (n=2,300) without comorbidity—has primary completion listed as April 2026 and overall completion as May 2026. Topline results may drop any day. The Phase 3 readout for the triple agonist that produced 28.7% weight loss in TRIUMPH-4 (in patients with obesity and knee osteoarthritis) will set the benchmark for the next-generation obesity drug class.

If TRIUMPH-1 produces comparable efficacy to TRIUMPH-4, retatrutide will be on a path to regulatory submission with the strongest efficacy profile of any obesity drug ever filed. The dysesthesia signal that emerged in TRIUMPH-4 (8.8% at 9 mg / 20.9% at 12 mg vs 0.7% placebo) will need to replicate or fail to replicate in the TRIUMPH-1 population—a population without the joint-pain comorbidity, in which the safety signal will read differently. The next two weeks could be the most consequential data event in obesity pharmacology since the original tirzepatide SURMOUNT trials.

The Broader Strategic Picture

Three things are visible in Lilly’s Q1 that weren’t a quarter ago.

The company is widening, not consolidating. Tirzepatide continues to grow at triple-digit rates. Foundayo is in market. Retatrutide is approaching its first non-comorbidity Phase 3 readout. Lilly’s posture is that of a company executing a multi-mechanism, multi-formulation portfolio strategy, with capital and clinical resources to advance all three programs in parallel rather than choosing among them.

The competitive gap with Novo Nordisk is widening. Novo reports Q1 next Tuesday, May 6—their first quarterly report since the CagriSema REDEFINE 4 head-to-head failure against tirzepatide in February, and after a 50% U.S. price-cut announcement effective January 2027. The contrast between Lilly’s raised guidance and Novo’s revised outlook (Novo previously guided for −5% to −13% adjusted sales growth at constant exchange rates for 2026) will be one of the more visible asymmetries in pharma earnings season.

The obesity drug category is no longer a binary. With Foundayo approved, retatrutide imminent, MariTide entering Phase 3, VK2735 and survodutide both with full Phase 3 data on the calendar, and the amylin agonist class advancing, the choice patients and physicians face is shifting from “which of two drugs” to “which of half a dozen mechanisms and formulations.” Lilly is positioned to compete in nearly all of those categories. Novo, after the CagriSema setback, is positioned to compete in fewer.

What’s on the Calendar

The next 30 days are dense with catalysts. TRIUMPH-1 topline could drop any day. Foundayo Week 4 IQVIA data will surface in the next IQVIA cycle. Novo reports Q1 May 6. The European Congress on Obesity runs May 12–15 in Istanbul, where Novo is presenting 52 abstracts including STEP UP higher-dose semaglutide (7.2 mg) data. Pfizer’s PF-3944 amylin agonist data is on the ADA Scientific Sessions calendar for June 6.

For the full evidence picture across the obesity pipeline—including evidence tier, mechanism, and trial portfolio for tirzepatide, retatrutide, semaglutide, and the rest—our weight-loss compound articles cover the current state of play.

References

1. Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines. Eli Lilly investor release. April 30, 2026. Lilly
2. Eli Lilly (LLY) earnings Q1 2026. CNBC. April 30, 2026. CNBC
3. Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand. Benzinga. 2026. Benzinga
4. Lilly’s posts another ‘blowout quarter’ as focus turns to Foundayo launch. BioPharma Dive. 2026. BioPharma Dive